- Date2025-02-10
Publication of Review Result of the 11th Pharmaceutical Reimbursement Evaluation Committee of 2024
□ The Health Insurance Review and Assessment Service (President Kang Jung-Gu) releases the results of the deliberations of the 11th Pharmaceutical Reimbursement Evaluation Committee in 2024 as follows.
○ Result of the review of the adequacy of the healthcare benefit for the pharmaceutical applied for assessment
|
Product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Omvoh 20mg/ ml, Omvoh prefilled pen injection, Syringe-inj100mg/ml (mirikizumab, recombinant DNA) |
Eli Lilly and Company Korea |
Ulcerative Colitis |
Reimbursement is adequate when accepted at or below assessed value. |
|
Ocrevus lnj (Ocrelizumab) |
Roche Korea, Inc |
Relapsing Remitting Multiple Sclerosis(RMS) |
Reimbursement is adequate when accepted at or below assessed value. |
|
Mylotarg Inj. 4.5mg(Gemtuzumab Ozogamicin) |
Pfizer |
Acute Myeloid Leukemia |
Non-Reimbursement |
※ Pursuant to Article 11(2) of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service evaluates the adequacy of reimbursement for drugs after deliberation by the Pharmaceutical Reimbursement Evaluation Committee. The detailed coverage of the pharmaceutical may differ from its efficacy and indications, and the final evaluation results may change if there are changes in reference products, modifications in the approval details of the requested product, or withdrawal(cancellation) of approval.
